What is Evonetix?
Evonetix is pioneering a novel approach to gene synthesis technology aimed at enhancing access to high-quality, gene-length DNA. Their innovative solutions are designed to empower researchers in various fields, including healthcare, agriculture, and manufacturing, by providing unprecedented speed and scale in gene synthesis. The company focuses on addressing critical global challenges through engineering biology, facilitating advancements in personalized medicine and other therapeutic areas. By establishing a gene foundry in every lab, Evonetix aims to accelerate the potential of engineering biology and drive significant innovations.
How much funding has Evonetix raised?
Evonetix has raised a total of $66.3M across 2 funding rounds:
Series A
$12.3M
Series B
$54M
Series A (2018): $12.3M with participation from DCVC Management, Morningside Group, Molten, and Providence Investment Advisors
Series B (2023): $54M led by Molten, Morningside Group, Rising Tide Fund, Providence Investment Company, Data Collective, Civilization Ventures, Foresite Capital, and Cambridge Consultants Ltd
Key Investors in Evonetix
Molten
Draper Esprit, founded in 2006 and headquartered in London, UK, is a venture capital firm, with offices in London, Cambridge, and Dublin. Investing in high-growth technology companies with global ambitions.
Morningside Group
Morningside USA is recognized for its excellence in the design and construction of notable urban buildings, including multi-family residential, retail, and commercial projects. The company's developments are built to the highest design and environmental standards using durable materials, enhancing community aesthetics and pride.
Foresite Capital
Foresite Capital is a multi-stage investment firm focused on transforming healthcare and life sciences by investing in companies that utilize biology and big data. The firm targets breakthrough opportunities at the intersection of technology and biotechnology.
What's next for Evonetix?
With the successful closure of this major enterprise-level funding, Evonetix is poised to transition from a research-focused entity to a commercial-scale powerhouse. The strategic roadmap involves the rapid deployment of its gene synthesis hardware, which is designed to integrate seamlessly into existing laboratory workflows. By focusing on the intersection of biology and digital technology, the company intends to reduce the barriers to entry for synthetic biology applications. Future efforts will likely prioritize the expansion of manufacturing capabilities and the establishment of strategic partnerships to solidify its market position as a foundational provider of genetic material for the next generation of therapeutic and industrial breakthroughs.
See full Evonetix company page
